

Worldwide Preclinical Co-Co Alliance for Small Molecule Compounds for Cancer

MAT2A, Pol Theta & Werner Helicase Synthetic Lethality Targets for Solid Tumors (6/20)

IDEAYA

- \$100M upfront payment
- \$20M eq at next Ideaya public offering
- Ideays pays early clin dev costs for MAT2A, subject to GSK option
- \$50M option exercise fee for MAT2A
- \$465-485M dev/reg milestones/product
- \$475M sales milestones/product

GSK

*Ideaya has option to pay 20% of dev costs for MAT2A & WER to obtain US 50% profit split

High Single-digit to Sub-Teen Royalties*

GSK has straight license to Pol Theta & WER, plus option to MAT2A